Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Gives Panel Presentation and Company Update at BIO InvestorForum; Announces Recent Close of $20 Million in Financing
Xencor Gives Panel Presentation and Company Update at BIO InvestorForum; Announces Recent Close of $20 Million in Financing MONROVIA, CA – October 18, 2005 – Xencor, Inc., a biotherapeutics company developing protein therapeutics and antibody drugs, announced today that Bassil Dahiyat, Ph.D.,
View HTML
Toggle Summary Xencor, Inc. Signs Collaboration with Centocor, Inc. to Improve Antibodies
Xencor, Inc. Signs Collaboration with Centocor, Inc. to Improve Antibodies Xencor, Inc. licenses engineered Fc domains to Centocor, Inc. to enhance therapeutic efficacy Monrovia, CA – July 18, 2005 – Xencor, Inc., a biotherapeutics company developing protein therapeutics and antibody drugs, today
View HTML
Toggle Summary FierceBiotech Honors Xencor as One of the
FierceBiotech Honors Xencor as One of the MONROVIA, CA – June 21, 2005 – Xencor, Inc., a company engineering superior biotherapeutics using its Protein Design Automation® technology, announced today that it has been selected as one of the “Fierce 15“ for 2005 by FierceBiotech, an internationally
View HTML
Toggle Summary Xencor Licenses Protein Variants to Lilly
Xencor Licenses Protein Variants to Lilly Monrovia, CA – April 13, 2005 – Xencor today announced that Eli Lilly and Company has exercised its option to develop one or more therapeutic proteins created by Xencor under its collaboration with Lilly. Xencor used its proprietary Protein Design
View HTML
Toggle Summary Xencor and Chugai Initiate Partnership for Optimized Antibodies
Xencor and Chugai Initiate Partnership for Optimized Antibodies Chugai licenses Xencor’s XmAb™ technology to enhance antibody efficacy Monrovia, CA – January 10, 2005 – Xencor today announced a license and collaboration agreement with Chugai Pharmaceutical Co., Ltd.
View HTML
Toggle Summary Xencor and Genentech to Collaborate to Develop Next-Generation Antibody Therapeutics
Genentech licenses Xencor’s XmAb™ technology for CD20 and Her2, key cancer and autoimmune targets
View HTML
Toggle Summary Xencor Announces Protein Optimization Collaboration with Lilly
Protein Design Automation platform enables Medicinal Chemistry for Proteins™
View HTML
Toggle Summary Xencor Determines Structure Of Baff, A Key Autoimmune Disease Target
Discovery Enables Dominant Negative Inhibitor Strategy and Clarifies BAFF Structural Controversy
View HTML
Toggle Summary Xencor and Protein Design Labs Initiate Partnership for Optimized Antibodies
PDL licenses Xencor XmAb™ technology to enhance antibody activity
View HTML
Toggle Summary Xencor Announces Bassil Dahiyat As Its New Chief Scientific Officer
Dahiyat launched Xencor’s biotherapeutic programs and protein design platform
View HTML